FENS 2022 | Developing blood-based biomarkers for stroke

Steffen Tiedt, PhD, Institute for Stroke and Dementia Research (ISD), Munich, Germany, gives an overview of the next steps in developing stroke-specific blood-based biomarkers. Technology advancements and increased knowledge provide a large window of opportunity for identifying novel biomarkers to improve diagnosis and guide clinical decision-making. A marker that could follow early neuronal injury over time would be highly valuable in clinical practice as well as makers of stroke etiology to identify the individual causes of stroke in patients. Identifying and validating blood-based biomarkers would tremendously impact the diagnosis, treatment, and prevention of stroke. This interview took place during the Federation of European Neuroscience Societies (FENS) 2022 Forum in Paris, France.